GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine, Shingrix ...

Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

Shingrix [Herpes Zoster vaccine (recombinant, AS01 B ix adjuvanted)] is a non-live, recombinant subunit vaccine indicated for the prevention of shingles (herpes zoster) and, in some markets ...

Researchers conducted an observational study to compare the risk for dementia associated with both the live and recombinant shingles vaccines.

Additionally, Dr. Brangman says that the Tdap vaccine, which protects against tetanus, diphtheria and whooping cough, is also ...

New Delhi: The Central Drugs Standard Control Organization (CDSCO) has published a list of the details of importers whose ...

Shingrix is approved to prevent shingles (herpes zoster) in adults aged 50 and older ... Also Read: GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like ...

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.